| Website | www.vectorialis.com |
| Field (and ATECO code) | 721010 |
| Target market | Transfection reagents for research, reagents for viral vector production, solutions for the ex vivo production of cell therapies, including CAR-T, and gene therapies; technologies for recombinant protein production. |
| Year of incorporation | 2026 |
Services
Vectorialis offers solutions and services for the formulation and optimization of nanoparticles for nucleic acid delivery. Services include support in reagent selection and optimization, development of transfection protocols, and process transfer across different production scales. Vectorialis also supports companies and research centers in optimizing upstream processes for the production of recombinant proteins and advanced therapies, providing tailored solutions based on specific application requirements.
Activities
Vectorialis’ proprietary platform integrates VibroFect®, a benchtop device, with a dedicated line of reagents that enable the formulation of highly biocompatible nanoparticles for nucleic acid-based drug delivery in a rapid, simple and reproducible manner. This non-viral technology is designed as an alternative to viral vectors and lipid nanoparticles, with applications ranging from biomedical research to recombinant protein production and the development of advanced therapies. Vectorialis offers high-efficiency reagents and supports the optimization of production processes.
Contacts
Vectorialis
E-mail:
n.bono@vectorialis.com
g.candiani@vectorialis.com
Social media:
https://www.linkedin.com/company/vectorialis/?viewAsMember=true
Founders
Discover the founders of Vectorialist
Co-founder & CEO, is Assistant Professor at Politecnico di Milano and tech co-inventor. She drives strategy, fundraising, partner relations, tech transfer, and commercialization.
Co-founder & President, is Full Professor at Politecnico di Milano with 15+ years in non-viral gene delivery. Co-inventor of VibroFect®, he leads R&D and academic strategy.